Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.62 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.62 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.62 |
| ▸ | LCK | P06239 | 2/20 | 0.58 |
| ▸ | NQO2 | P16083 | 1/20 | 0.58 |
| ▸ | HNF4A | P41235 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.56 |
| ▸ | AR | P10275 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1603721 | 1.00 | PTPN1 (0.62) | PTPN1PTPN2PTPN6LCKNQO2 | |
| SCHEMBL1603423 | 0.84 | PTPN1 (0.89) | PTPN1PTPN2PTPN6LCKNQO2 | |
| SCHEMBL1603420 | 0.84 | PTPN1 (0.89) | PTPN1PTPN2PTPN6LCKNQO2 | |
| SCHEMBL14898191 | 0.81 | KDM4E (0.66) | PTPN1PTPN2PTPN6LCKHNF4A | |
| SCHEMBL4758193 | 0.79 | PTGS2 (0.57) | PTPN1PTPN2PTPN6LCKHNF4A | |
| SCHEMBL29953251 | 0.79 | PTGS2 (0.57) | PTPN1PTPN2PTPN6LCKHNF4A | |
| SCHEMBL15780784 | 0.79 | PTGS1 (0.67) | PTPN1PTPN2PTPN6HNF4APTGS2 | |
| SCHEMBL1163541 | 0.78 | CA12 (0.64) | PTGS2CHRNA7MAPTHPGDSIRT1 | |
| SCHEMBL10781901 | 0.78 | CA12 (0.64) | PTGS2CHRNA7MAPTHPGDSIRT1 | |
| SCHEMBL1048686 | 0.77 | PTPN1 (1.00) | PTPN1PTPN2PTPN6LCKHNF4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242144-B2 | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-08-14 | — | — | US | disclosed |
| US-8242144-B2 | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-08-14 | — | — | US | disclosed |
| US-8242144-B2 | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-08-14 | — | — | US | disclosed |
| US-20110082176-A1 | Stilbenes and Chalcones for the Prevention and Treatment of Cardiovascular Diseases | RESVERLOGIX CORP. | 2011-04-07 | — | — | US | disclosed |
| US-20110082176-A1 | Stilbenes and Chalcones for the Prevention and Treatment of Cardiovascular Diseases | RESVERLOGIX CORP. | 2011-04-07 | — | — | US | disclosed |
| US-20110082176-A1 | Stilbenes and Chalcones for the Prevention and Treatment of Cardiovascular Diseases | RESVERLOGIX CORP. | 2011-04-07 | — | — | US | disclosed |
| US-7846915-B2 | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases | Resverlogix Corporation (CA) | 2010-12-07 | — | — | US | disclosed |
| US-7846915-B2 | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases | Resverlogix Corporation (CA) | 2010-12-07 | — | — | US | disclosed |
| US-7846915-B2 | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases | Resverlogix Corporation (CA) | 2010-12-07 | — | — | US | disclosed |
| US-20060205792-A1 | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases | HEPALINK (HONG KONG) LIMITED (HK) | 2006-09-14 | — | — | US | disclosed |
| WO-2006045010-A2 | STILBENES AND CHALCONES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205792-A1 | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases | APOB, APOL1, HDLBP | PTPN1 93/4885PTPN2 287/4885PTPN6 152/4885 |
| US-20110082176-A1 | Stilbenes and Chalcones for the Prevention and Treatment of Cardiovascular Diseases | APOB, APOL1, HDLBP | PTPN1 93/4885PTPN2 287/4885PTPN6 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.